Abstract: A battery cell includes an electrode assembly, a pair of electrode leads electrically connected to the electrode assembly, a battery case configured to accommodate the pair of electrode leads such that the pair of electrode leads protrude at least partially in a front and rear direction of the battery cell, the battery case having an accommodation space formed to accommodate the electrode assembly, and a taping unit configured to integrally cover both side surfaces and upper and lower surfaces of the battery case.

Abstract: A battery module includes: a battery cell assembly having a plurality of battery cells; a top plate configured to cover an upper side of the battery cell assembly; a bottom plate configured to cover a lower side of the battery cell assembly; a sensing assembly disposed to cover a front side and a rear side of the battery cell assembly; a pair of side plates disposed at side surfaces, respectively, of the battery cell assembly; and a pair of compression pads disposed between the pair of side plates and the battery cell assembly, respectively.

Abstract: The present invention relates to a novel Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate (MSG), and a functional health food, a pharmaceutical composition, or a food product comprising the same as an active ingredient. More specifically, the strain is effective in reducing in vivo blood MSG levels of animals and attenuating MSG Symptom Complex, and thus can be used in a functional health food, a pharmaceutical composition, or a food product aiming to prevent in vivo absorption of MSG, which is known to be harmful, and improve the MSG Symptom Complex.

Abstract: The present invention relates to a novel Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate (MSG), and a functional health food, a pharmaceutical composition, or a food product comprising the same as an active ingredient. More specifically, the strain is effective in reducing in vivo blood MSG levels of animals and attenuating MSG Symptom Complex, and thus can be used in a functional health food, a pharmaceutical composition, or a food product aiming to prevent in vivo absorption of MSG, which is known to be harmful, and improve the MSG Symptom Complex.

Abstract: An orally administered composition for improving food absorption and digestion contains therapeutically effective dosages of digestive enzymes and L-glutamine as active ingredients. The digestive enzymes include at least one each of a lipase, a protease, and an amylase, and at least a portion of each of these enzymes is enteric coated.